The imprecision of measuring activated clotting time (ACT) from the guiding catheter during percutaneous coronary interventions

Cardiovasc Revasc Med. 2024 Nov:68:98-100. doi: 10.1016/j.carrev.2024.05.006. Epub 2024 May 6.

Abstract

Background: Finding the balance between the reduction in ischemic events and bleeding complications is crucial for the success of percutaneous coronary intervention (PCI). The activated clotting time (ACT) is used routinely worldwide to monitor and titrate anticoagulation therapy with unfractionated heparin (UFH) during the procedure.

Objectives: We aimed to test the accuracy of ACT measurements from the guiding catheter compared to the arterial access sheath.

Methods: Patients undergoing PCI with UFH therapy were prospectively enrolled. Blood samples were drawn from the coronary guide catheter and the arterial access sheath. ACT values were determined in the same ACT machine, and potential interactions with clinical variables were analyzed.

Results: The study included 331 patients with post PCI ACT measurements. The mean ACT value of the catheter samples was statistically higher than the arterial access sample [294 ± 77 s Vs. 250 ± 60 s, p < 0.001]. The mean difference between the guiding catheter and the arterial line sheath samples was 43 ± 27 s (P < 0.001). We found that in 101/331 [30 %] patients the ACT from the guiding catheter was above 250 s, while from the access sheath it was below 250 s. Notably, in 40/331 [12 %] the ACT from the guiding catheter was above 200 s, while from the access sheath it was below 200 s.

Conclusions: Large proportion of patient may be considered to have therapeutic ACT if measured from guide catheter during PCI, while the corresponding ACT from arterial sheath is subtherapeutic. This difference may have clinical and safety significance.

Keywords: Activated clotting time (ACT); Anticoagulation therapy; Bleeding complications; Percutaneous coronary intervention (PCI); Safety; Unfractionated heparin.

Publication types

  • Comparative Study
  • Letter

MeSH terms

  • Aged
  • Anticoagulants* / administration & dosage
  • Anticoagulants* / adverse effects
  • Blood Coagulation* / drug effects
  • Cardiac Catheterization* / adverse effects
  • Cardiac Catheterization* / instrumentation
  • Cardiac Catheters*
  • Catheterization, Peripheral / adverse effects
  • Coronary Artery Disease / blood
  • Coronary Artery Disease / diagnostic imaging
  • Coronary Artery Disease / therapy
  • Drug Monitoring / methods
  • Female
  • Heparin* / administration & dosage
  • Heparin* / adverse effects
  • Humans
  • Male
  • Middle Aged
  • Percutaneous Coronary Intervention* / adverse effects
  • Percutaneous Coronary Intervention* / instrumentation
  • Predictive Value of Tests*
  • Prospective Studies
  • Reproducibility of Results
  • Time Factors
  • Treatment Outcome
  • Whole Blood Coagulation Time

Substances

  • Anticoagulants
  • Heparin